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Abstract
Background: Since mediators of inflammation are associated with insulin resistance, and the risk of developing diabetes
mellitus and gestational diabetes, we hypothesized that genetic variation in members of the inflammatory gene pathway
impact glucose levels and related phenotypes in pregnancy. We evaluated this hypothesis by testing for association
between genetic variants in 31 inflammatory pathway genes in the Hyperglycemia and Adverse Pregnancy Outcome
(HAPO) cohort, a large multiethnic multicenter study designed to address the impact of glycemia less than overt diabetes
on pregnancy outcome.
Results: Fasting, 1-hour, and 2-hour glucose, fasting and 1-hour C-peptide, and HbA1c levels were measured in blood
samples obtained from HAPO participants during an oral glucose tolerance test at 24-32 weeks gestation. We tested for
association between 458 SNPs mapping to 31 genes in the inflammatory pathway and metabolic phenotypes in 3836
European ancestry and 1713 Thai pregnant women. The strongest evidence for association was observed with TNF alpha
and HbA1c (rs1052248; 0.04% increase per allele C; p-value = 4.461025), RETN and fasting plasma glucose (rs1423096;
0.7 mg/dl decrease per allele A; p-value = 1.161024), IL8 and 1 hr plasma glucose (rs2886920; 2.6 mg/dl decrease per allele
T; p-value = 1.361024), ADIPOR2 and fasting C-peptide (rs2041139; 0.55 ug/L decrease per allele A; p-value = 1.461024),
LEPR and 1-hour C-peptide (rs1171278; 0.62 ug/L decrease per allele T; p-value = 2.461024), and IL6 and 1-hour plasma
glucose (rs6954897; 22.29 mg/dl decrease per allele G, p-value = 4.361024).
Conclusions: Based on the genes surveyed in this study the inflammatory pathway is unlikely to have a strong impact on
maternal metabolic phenotypes in pregnancy although variation in individual members of the pathway (e.g. RETN, IL8,
ADIPOR2, LEPR, IL6, and TNF alpha,) may contribute to metabolic phenotypes in pregnant women.
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Introduction
There is a well-established link between obesity, diabetes, and
insulin resistance and chronic low levels of inflammation (reviewed
in [1]). This link is based on multiple lines of evidence. First,
markers of the inflammatory response such as tumor necrosis
factor-alpha (TNF-alpha), interleukin-1b (IL-1b), interleukin 6 (IL-
6), plasminogen activator inhibitor 1 (PAI1), and C-reactive
protein (CRP) are strongly associated with features of the
metabolic syndrome in humans [2,3,4,5,6,7,8,9,10,11,12,13,
14,15,16,17]. Second, mouse knockout strains of IL-6 [18],
TNF-alpha [19], PAI-1 [20], IL-18 [21], IL-1a [22], resistin
[23], monocyte chemotactic protein-1 (MCP-1) [24,25], inter-
cellular adhesion molecule 1 (ICAM-1) [26], nitric oxide synthase
(iNOS) [27], inhibitor of nuclear factor kappa-B kinase subunit
beta (IKK-b) [28,29], jun N-terminal kinase 1 (JNK1) [30], and
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suppressor of cytokine signaling 1 (SOCS1) [31] have perturba-
tions in measures of insulin resistance or blood glucose levels.
Third, patients with chronic inflammatory conditions such as
chronic hepatitis C, rheumatoid arthritis, and inflammatory lung
disease are at increased risk for developing diabetes (reviewed in
[32,33]). Lastly, genetic or pharmacological removal or reduction
of inflammatory factors can protect humans and high-risk rodent
models against insulin resistance independent of obesity, indicating
that the inflammatory response plays a primary role in the etiology
of insulin resistance and diabetes rather than an effect secondary to
obesity.
Many of the effects of the inflammatory response on insulin
resistance are mediated via the nuclear factor kappa B (NF-kB)
signalling pathway [29,34,35,36]. NF-kB is a transcription factor
that regulates multiple cellular processes including cell growth,
survival and division, apoptosis, stress, hypoxia, and immune
function. Upon stimulation by cytokines, NF-kB is activated by
IKK-b and translocated into the nucleus where it regulates
transcription of a broad range of genes including the pro-
inflammatory cytokines, IL-1, IL-6 and TNF-alpha. Ablation of
IKK-b in the liver of mice reduces the induction of IL-1a, IL-1b,
IL-6, and RANTES cytokine mRNA in liver by high fat diet [37].
Several studies have demonstrated the effects of disruption of the
NF-kB pathway on insulin sensitivity. For example elevated levels
of TNF-alpha result in insulin resistance [36,38,39,40,41]. In
hepatocytes, over-expression of a specific inhibitor of NF-kB
activation, IkB, prevents an IL-1b-induced decrease in insulin
sensitivity [37]. Furthermore, nonsteroid anti-inflammatory drugs,
including aspirin and sodium salicylate which suppress IkB
proteolysis by inhibiting IKK-b [42], improve insulin resistance
and glycemia [43,44].
During pregnancy the levels of the pro-inflammatory cytokines
CRP and TNF-alpha are positively associated with fasting insulin
and body mass index (BMI), respectively [45]. In women with
gestational diabetes, levels of the anti-inflammatory cytokine,
adiponectin, are negatively associated with gestational diabetes
while TNF-alpha and its soluble receptors sTNFR-1 and sTNFR-
2 are positively associated [46,47]. Furthermore, Lowe et al have
shown that among non diabetic pregnant women levels of the pro-
inflammatory cytokines PAI-1 and CRP are positively associated
with maternal glucose, BMI and C-peptide levels while the levels
of the anti-inflammatory cytokine, adiponectin, are negatively
correlated with the same phenotypes [48].
To date inflammatory pathway genes have not been shown to
play a major role in type 2 diabetes or glucose tolerance. However,
most of these results are based on genome wide association studies
(GWAS) which do not always provide sufficient genetic coverage
of any given gene region. The more exhaustive tagging approach
possible in a candidate gene screen may, therefore, detect genetic
loci not identified by GWAS.
Since pregnancy is an insulin resistant state, the inflammatory
pathway may also be important in glucose regulation during
pregnancy and the development of gestational diabetes. To
determine whether variation within inflammatory pathway genes
impacts glucose regulation during pregnancy and the development
of gestational diabetes we tested for association between 31 genes
(Table 1) within the inflammatory gene pathway densely tagged
with 458 genetic single nucleotide polymorphisms (SNPs, Tables 2
and 3) and measures of maternal metabolism in 5549 mothers of
the Hyperglycemia and Adverse Pregnancy Outcome (HAPO)
cohort, a large multiethnic, multicenter study designed to address
the impact of glycemia less than overt diabetes on pregnancy
outcome [49].
Results
To evaluate the impact of the inflammatory gene pathway on
glycemia during pregnancy we carried out an association study.
We genotyped 508 SNPs mapping to 31 inflammatory genes
(Tables 1, 2, 3) in 6218 pregnant women of the HAPO cohort. We
tested for association between these genetic markers and six
maternal metabolic phenotypes (fasting, 1-hour and 2-hour
glucose levels from the OGTT, fasting and 1-hour C-peptide
levels from the OGTT, and HbA1C). Each phenotype was tested
under a minimally adjusted statistical model and a fully adjusted
model.
Association Testing
The most statistically significant results of the association
analyses are shown in Table 4. Two models were analyzed for
each outcome. Model I was a minimally adjusted model that
included adjustment for field center, ethnicity using the first two
principal components, maternal age, parity, gestational age at
OGTT, and neonatal gender. Model II was the fully adjusted
model, adjusting for all covariates included in model I as well as
mean arterial pressure at OGTT, maternal BMI at OGTT, and
maternal height at OGTT. While none of our findings reach
formal genome wide statistical significance (p-value,161028
[50]), several SNPs do show evidence for association (defined as
p,5.061024) with maternal phenotypes during pregnancy. We
arbitrarily selected p,5.061024 as nominally significant since it
corresponds to a corrected p-value of 0.05 after correction for 100
independent gene regions and the 508 SNPs analyzed in the study
fell into ,100 independent linkage disequilibrium blocks.
Association with glucose levels
Multiple genes showed evidence for association with glucose
levels. The strongest evidence for association with glucose levels
was with variants in the genomic region for resistin (RETN). There
was evidence for association with the SNP rs1423096, which maps
5 kb 59 to RETN and fasting plasma glucose (FPG) levels (p-value
1.161024 with Model 1) in the complete cohort (Table 4;
Figure 1A). Although each cohort by itself demonstrated only
moderate evidence for association, the effect size of rs1423096 was
very similar in the European ancestry (b=20.74 to 20.84 mg/
dl), Thai (b=20.47 to 20.55 mg/dl), and combined cohorts
(b=20.62 to 20.72 mg/dl) under each model tested. Thus, these
data support a role for rs1423096 on FPG levels in both cohorts
and demonstrate that this effect is not sensitive to potential
confounding factors.
Two variants (rs2227306, and rs2886920) in the gene encoding
interleukin 8 (IL8) were associated with 1-hour plasma glucose
levels (1-hour PG) at p,5.061024 with essentially the same effect
size for each SNP (Table 4; Figure 1B). Although the evidence for
association is substantially stronger in the European ancestry
cohort, the effect, while not statistically significant, is in the same
direction in the Thai cohort. These two SNPs are in linkage
disequilibrium and, therefore, are likely detecting the same genetic
signal.
A SNP mapping 17 kb upstream of interleukin 6, IL6
(rs6954897) is negatively associated with 1-hour plasma glucose
levels with Model 1 in the European ancestry cohort (b=22.245,
p-value = 9.561024; Table 4, Figure 1C). Although the effect size
was very similar in the Thai population (b=23.044) the findings
did not reach statistical significance due to the reduced MAF
(0.056 vs. 0.428 in the European ancestry cohort) of rs6954897
and smaller sample size in the Thai population. However, in the
analysis of all samples in model 1, this SNP demonstrated
Inflammatory Pathway Variation during Pregnancy
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association with 1-hour plasma glucose ((b=22.291, p-val-
ue = 4.361024; Table 4, Fig. 1C).
Association with C-peptide levels
The adiponectin receptor 2 (ADIPOR2) SNP, rs2041139, was
associated with fasting C-peptide levels in the European ancestry
cohort (b= 0.548, p-value = 1.461024 in Model 1; Table 4,
Figure 1D) but only to a much lesser degree in the Thai cohort
(b= 0.031, p-value = not significant). It should be noted that the
minor allele frequency (MAF) for rs2041139 is very low in the
Thai population (MAF = 0.005); therefore the findings at this locus
may not be very robust and need to be interpreted with caution.
Two SNPs within the leptin receptor, LEPR (rs1627238 and
rs1171278) were associated with 1-hour C-peptide levels in the
Thai cohort (Table 4 and Figure 1E; (b= 0.61–0.62, p-
value = 2.961024 and p-value = 2.461024 respectively). Neither
marker showed significant evidence for association in the
European ancestry cohort. Both markers map within a two kb
fragment of intron 2 of LEPR and are in strong LD with each other
(Figure 1E).
Association with HbA1C levels
The strongest evidence for association with HbA1C and in the
overall study (p-value = 4.4261025) was observed with rs1052248
in the tumor necrosis factor alpha gene, TNF, under the fully
adjusted model in the complete cohort (Table 4; Figure 1G).
rs1052248 was associated with HbA1c with somewhat stronger
effect size in the Thai cohort than the European derived cohort
((b= 0.057 vs. 0.029 in Model 2). One other SNP in TNF
(rs11575839) also have evidence of association (p,5.061024)
with HbA1c. In each case the strongest evidence was in the
combined cohort with some evidence for association in both
populations.
SNPs in several genes showed evidence for association in only
one cohort or the effect was in the opposite direction in the Thai
and European ancestry cohorts (Table 4). These include
rs7554506 in adiponectin receptor 1, ADIPOR1, with 1-hour C-
peptide levels under the fully adjusted model (Model 2). This
association was only observed in the Thai cohort.
Table 1. List of genes.
Gene ID Chr. Location Gene name
ADIPOQ 3q27.3 adiponectin precursor
ADIPOR1 1q23.1 adiponectin receptor 1
ADIPOR2 12p13.33 adiponectin receptor 2
CCL2 17q12 small inducible cytokine A2 precursor
CRP 1q32.2 C-reactive protein precursor
CTLA4 2q33.2 cytotoxic T-lymphocyte-associated protein 4
IFIH1 2q24.2 Interferon-induced helicase C domain-containing protein 1
IL10 1q32.1 interleukin 10 precursor
IL18 11q23.1 interleukin 18 proprotein
IL18R1 2q11.2 interleukin 18 receptor 1 precursor
IL1RL1 2q11.2 interleukin 1 receptor-like 1 precursor
IL1A 2q13 interleukin 1, alpha proprotein
IL1B 2q13 interleukin 1, beta proprotein
IL1R1 2q11.2 interleukin 1 receptor, type I precursor
IL1R2 2q11.2 interleukin 1 receptor, type 2 precursor
IL1RL2 2q11.2 interleukin 1 receptor-like 2 precursor
IL1RN, IL1RA 2q13 interleukin 1 receptor antagonist
IL6 7p15.3 interleukin 6
IL6R 1q21.3 interleukin 6 receptor isoform 2 precursor
IL8 4q13.3 interleukin 8 precursor
IL8RA 2q35 interleukin 8 receptor alpha
IL8RB 2q35 interleukin 8 receptor beta
KL 13q13.1 Klotho
LEP 7q32.1 leptin precursor
LEPR 1p31.2 leptin receptor
NFKB1 4q24 nuclear factor kappa-B, subunit 1
NFKB2 10q24.32 nuclear factor of kappa light polypeptide gene
NOD2 16q12.1 nucleotide-binding oligomerization domain
PAI1 (SERPINE1) 7q22.1 plasminogen activator inhibitor-1
RETN 19p13.2 Resistin
TNF 6p21.33 tumor necrosis factor alpha
doi:10.1371/journal.pone.0032958.t001
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Discussion
In a screen of 31 genes encoding members of the inflammatory
pathway, we identified several with evidence for association with
metabolic phenotypes in pregnant women. In particular the genes
for cytokines including TNF, RETN, IL6, and IL8 were associated
with glucose levels during pregnancy. Two receptors for cytokines
(ADIPOR2 and LEPR) were associated with fasting and 1-hour C-
peptide levels respectively.
A large number of GWAS have been carried out for type 2
diabetes and intermediate phenotypes such as fasting glucose levels
[51,52,53,54,55,56,57,58,59,60,61,62,63,64,65]. However, no
member of the inflammatory gene pathway was identified among
the approximately 40 type 2 diabetes susceptibility loci identified
to date nor was there evidence for association with diabetes related
phenotypes. These observations can be due to several factors. For
one GWAS genotyping arrays on average interrogate 80% of the
human genome and therefore may not have exhaustive coverage
of specific genic regions of interest. Second, the effect size of the
inflammatory genes may be too modest to reach genome-wide
significance. Small effect sizes may still be detected in a candidate
gene approach due to the reduced level of multiple testing
correction that is required. In fact none of our findings reached
genome wide significance and would therefore not have been
detected in a GWAS. To evaluate the effect of genetic variations in
genes in the inflammatory pathway on maternal glycemia during
pregnancy with greater sensitivity than possible with current
GWAS arrays, we designed a genotyping array with exhaustive
coverage containing 458 SNPs in 31 genes belonging to the
inflammatory pathway. In addition to tagging SNPs, we also
included any known coding variants (cSNPs) mapping to the
candidate genes and any SNPs previously identified as candidate
SNPs (candSNPs) within the candidate genes (highlighted in
Table 3).
While the loci with strongest evidence for association with
metabolic traits in our study have not been reported in published
GWAS, it is possible that they are associated at significance levels
below the traditional cut-off reported in these studies. In fact
multiple markers in both ADIPOR1 and IL8 do show evidence (p-
value,0.01) for association with metabolic measures in the
MAGIC consortium (Meta-Analyses of Glucose and Insulin-
related traits Consortium) meta analysis results [61,66]. Notably
there was no evidence for association with markers mapping to
LEPR, TNF, IL6, ADOPOR2, or RETN even in the same SNP that
was associated in our study as was the case for LEPR, TNF, IL6,
and RETN. Markers within IL10 were nominally associated with
glucose levels (p-value ,0.02) in the MAGIC consortium. One
potential explanation for these observations is that some of our
findings are unique to pregnancy (LEPR, TNF, IL6, and RETN)
while others are also observed in the non-pregnant population.
This would not be surprising since during pregnancy there is an
increase of the inflammatory response due to both the general
insulin resistant state of pregnancy and due to placentally derived
factors.
Replication of genetic association results is critical for the
validation of a potential susceptibility locus. In this study we
analyze two large cohorts of European and Asian ancestry. Not
only does this allow us to replicate our results from one cohort in
the other, it also provides evidence for the generalizability of our
findings to global populations. As is the case for most other
common diseases, genetic analysis of the inflammatory gene
pathway in metabolic phenotypes has been predominantly limited
to populations of European ancestry. In our study 16 out of 17 of
our strongest signals show evidence for association that is
consistent in both populations (i.e. in the same direction).
The genetic effect of some of the inflammatory genes
highlighted in this study has been previously studied. Variants
within IL18, IL1RN, IL6R, and PAI1 showed no evidence for
association with type 2 diabetes in a large meta- analysis [67]. In
an in-depth analysis Boraska et al tested for association between
type 2 diabetes and nine tagging SNPs mapping to the TNF
alpha/LTA gene region in 1520 cases and 2570 controls but found
no evidence for association [68]. Hivert et al tested for association
between 21 tagging SNPs in RETN and diabetes related traits in
2531 members of the Framingham Offspring Study cohort [69].
They found significant evidence for association 39 to RETN with
both resistin and fasting glucose levels. Although, they tested
rs1423096 which is the variant we found to be associated with
fasting glucose levels in this study (Table 4 and Figure 1A), the
strongest evidence for association with glucose in the Framingham
Offspring Study was with rs10401670 which maps 3,626 bp
downstream of rs1423096. We detect no evidence of association
between rs10401670 and any phenotypes tested in the HAPO
cohort. Hivert et al carried out a similar analysis for 22 tagging
SNPs mapping to the adiponectin gene (ADIPOQ). They found









ADIPOQ 3q27.3 16 11 11
ADIPOR1 1q23.1 18 14 13
ADIPOR2 12p13.33 98 28 26
CCL2 17q12 1.9 0 0
CRP 1q23.2 2.3 0 0
CTLA4 2q33.2 6.2 0 0
IFH1 2q24.2 8.4 0 0
IL10 1q32.1 5 18 16
IL18 11q23.1 21 12 12
IL1RL1/IL18R1 2q11.2 60 30 28
IL1A/IL1B 2q13 64 24 19
IL1R1 2q11.2 113 19 19
IL1R2 2q11.2 37 24 20
IL1RL2 2q11.2 52 12 12
IL1RN/IL1RA 2q13 33 21 22
IL6 7p15.3 4.8 19 18
IL6R 1q21.3 63 23 20
IL8 4q13.3 3.2 11 9
IL8RA,B 2q35 43 16 16
KL 13q13.1 50 0 0
LEP 7q32.1 16 16 15
LEPR 1P31.2 217 75 74
NFKB1 4q24 116 43 41
NFKB2 10q24.32 7.9 9 9
NOD2 16q12.1 11 0 0
PAI (SERPINE1) 7q22.1 12 2 0
RETN 19p13.2 1.4 12 12
TNF 6p21.33 2.8 15 15
*htSNPs =Haplotype tagged SNPs.
doi:10.1371/journal.pone.0032958.t002
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evidence for association with the C allele of nonsynonymous SNP
in exon 3 of the gene (rs17366743, Y111H) and diabetes and
fasting plasma glucose levels. While we do not observe statistically
significant evidence for association between this variant and
glucose levels in our study, there is a trend for association with the
C-allele of rs17366743 with 2-hour plasma glucose in European
ancestry pregnant women (p-value = 0.081). It should be noted
that, while T2D and elevated glucose levels during pregnancy are
related phenotypes, they are not identical and may therefore have
different susceptibility loci.
To date most of genetic studies of the role of inflammatory
genes in metabolic phenotypes have been limited to one or two
functional variants per gene and small sample sizes (n,1000). The
impact of genetic variation within the leptin receptor (LEPR) on
metabolic phenotypes has been intensively studied but the findings
remain ambiguous. For instance, both alleles of the coding variant
Gln223Arg (rs1137101) of the LEPR have shown evidence for
association with increased BMI. While we did see nominal
evidence for association between rs1137101 and HBA1C levels in
the Thai population and 1-hour C-peptide levels in the Caucasian
cohort (data not shown), these results did not reach significance as
defined in our study. To date no major studies have been carried
out to systematically assess the impact of this pathway on maternal
metabolic phenotypes during pregnancy.
Past studies have shown clear evidence for association between
protein levels of various members of the inflammatory pathway
and metabolic phenotypes including insulin resistance, type 2
diabetes, and obesity. However these studies cannot provide
evidence for the directionality of the effect – in other words does
insulin resistance lead to perturbations of the inflammatory
pathway or vice versa. Genetic studies such as the one presented
here can address this question. Our data support the hypothesis
that variation within the inflammatory pathway itself impacts
metabolic phenotypes during pregnancy rather than the reverse.
Although several of the findings presented here (association
between TNF alpha and HbA1c, IL8 and 1-hour plasma glucose,
IL6 and 1-hour plasma glucose, and RETN and fasting plasma
glucose) show clear evidence for association in independent
populations and therefore provide evidence of replication within
this cohort, further studies are needed to determine whether the
findings presented here are limited to pregnancy or can be
expanded to other phenotypic groups.
Conclusions
Based on the genes surveyed in this study, we observed
significant evidence for association between members of the
inflammatory gene pathway and several metabolic measures
during pregnancy. Specifically, cytokines were associated with
fasting glucose (RETN), 1-hour plasma glucose levels during the
OGTT (IL6, IL8) and HbA1C levels (IL10, TNF) while cytokine
receptors were associated with fasting (ADIPOR2) or 1-hour C-
peptide (LEPR) levels. Thus, this study suggests that while some
members of the inflammatory gene pathway are associated with
metabolic phenotypes in pregnant women, the inflammatory
Table 3. Disease associated SNPs (candSNPs) and coding variant SNPs (cSNPs).
Variant Gene Chr. Location Amino Acids
rs266729 ADIPOQ candSNP [76,77,78] 3q27.3 59 of gene
rs1501299 ADIPOQ candSNP [79,80,81,82] 3q27.3 +276G.T
rs17366743 ADIPOQ cSNP. candSNP [83,84] 3q27.3 Tyr111His
rs1024610 CCL2 candSNP 17q12 59 of gene
rs991804 CCL2 candSNP 17q12 intronic
rs1130864 CRP candSNP [85,86,87] 1q23.2 intronic
rs1800947 CRP candSNP [85,86,87] 1q32.2 Leu184Leu
rs3087243 CTLA4 candSNP 2q33.2 39 of gene
rs1990760 IFIH1 cSNP, candSNP [88,89,90,91,92,93] 2q24.2 Ala946Thr
rs16944 IL1A/IL1B candSNP [94] 2q13 intronic
rs6731822 IL1A/IL1B cSNP 2q13 Ile375Val
rs1800871 IL10 candSNP [95,96] 1q32.1 59 of gene
rs1800896 IL10 candSNP [96,97] 1q32.1 59 of gene
rs1800872 IL10 candSNP [95,96] 1q32.1 59 of gene
rs5744256 IL18 candSNP [98] 11q23.1 intronic
rs4251961 IL1RN, IL1RA candSNP [99,100,101] 2q13 intronic
rs315943 IL1RN, IL1RA candSNP 2q13 39 of gene
rs1800795 IL6 candSNP [102,103,104,105,106,107] 7p15.3 intronic
rs952146 IL6R candSNP 1q21.3 59 of gene
rs4537545 IL6R candSNP [105,108] 1q21.3 intronic
rs2229238 IL6R candSNP [109] 1q21.3 39 UTR
rs9536314 KL candSNP and cSNP [110] 13q13.1 Phe352Val
rs12324931 NOD2 16q12.1 59 of gene
rs6465787 PAI1 canSNP [111] 7q22.1 59 of gene
rs2227631 PAI1 candSNP [111] 7q22.1 59 of gene
doi:10.1371/journal.pone.0032958.t003
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pathway is unlikely to have a strong impact on maternal
metabolism.
Methods
HAPO was an international, multi-center epidemiologic study
conducted at 15 centers in 9 countries. The HAPO study was
approved by the local institutional review board at each center.
The centers contributing subjects studied in this work are Bangkok
(Rajavithi Hospital, Ministry of Public Health), Manchester
(Health and Social Care Trust Research Ethics Committee),
Belfast (Health and Social Care Trust Research Ethics Commit-
tee), Brisbane (Mater Medical Research Institute), and Newcastle
(Hunter Area Research Ethics Committee). All participants gave
Table 4. Results of Association Studies.
Model 1 Model 2
Phenotype Gene SNP Allele Cohort MAF* N** Beta p Beta p
1 hour
C-peptide (ug/L)
ADIPOR1 rs7554506 A Eur. Anc. 0.355 3830 0.021 *** 0.013 ***
Thai 0.086 1713 20.572 0.0026 20.065 0.0005




ADIPOR2 rs2041139 A Eur. Anc. 0.005 3800 0.548 0.00014 0.313 0.00850
Thai 0.043 1710 0.031 *** 0.029 ***
All 0.017 5510 0.138 0.02658 0.083 ***
1 hour PG
(mg/dl)
IL6 rs6954897 G Eur. Anc. 0.428 3833 22.245 0.00095 21.814 0.00600
Thai 0.056 1710 23.044 *** 23.349 ***
All 0.413 5543 22.291 0.00043 21.935 0.00231
1 hour PG
(mg/dl)
IL8 rs2227306 T Eur. Anc. 0.439 3833 22.496 0.00020 22.231 0.00063
Thai 0.330 1709 20.399 *** 20.434 ***
All 0.405 5542 21.903 0.00086 21.748 0.00175
1 hour PG
(mg/dl)
IL8 rs2886920 T Eur. Anc. 0.438 3833 22.552 0.00013 22.297 0.00040
Thai 0.426 1709 20.868 *** 20.812 ***
All 0.434 5542 22.045 0.00026 21.864 0.00065
1 hour C-peptide
(mg/L)
LEPR rs1171278 T Eur. Anc. 0.179 3833 20.040 *** 20.056 ***
Thai 0.097 1713 20.573 0.00086 20.620 0.00024
All 0.154 5546 20.144 *** 20.167 0.03161
1 hour C-peptide
(mg/L)
LEPR rs1627238 T Eur. Anc. 0.179 3835 20.038 *** 20.049 ***
Thai 0.097 1713 20.564 0.00104 20.613 0.00029





RETN rs1423096 A Eur. Anc. 0.103 3833 20.843 0.00078 20.742 0.00136
Thai 0.207 1712 20.554 0.04514 20.470 ***
All 0.135 5545 20.721 0.00011 20.620 0.00039
HbA1c
(%)
TNF rs1052248 A Eur. Anc. 0.264 3648 0.027 0.00427 0.029 0.00140
Thai 0.361 1567 0.063 0.00747 0.057 0.01296
All 0.294 5215 0.039 6.9961025 0.040 4.4261025
HbA1c
(%)
TNF rs11575839 T Eur. Anc. 0.017 3647 0.004 *** 0.010 ***
Thai 0.087 1568 0.121 0.00313 0.122 0.00257
All 0.039 5215 0.082 0.00052 0.086 0.00025
*MAF – minor allele frequency.
**number of subjects included in the analysis.
***p-value.0.05.
doi:10.1371/journal.pone.0032958.t004
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written informed consent. An external Data Monitoring Commit-
tee provided oversight. Study methods have been published
[70,71,72]. A brief overview is presented here.
Participants
All pregnant women at each field center were eligible to
participate unless they had one or more exclusion criteria [70].
Gestational age and the expected date of delivery were determined
as previously described [70].
Oral glucose tolerance test (OGTT)
All participants underwent a standard 75-gram OGTT between
24 and 32 weeks gestation and as close to 28 weeks as possible.
Plasma glucose samples were collected at fasting and one- and
two-hours after the glucose load. Samples for serum C-peptide
were collected at fasting and one-hour time points (Table 5).
Anthropometric measurements
Height, weight, and blood pressure were measured at the
OGTT visit using standardized procedures and calibrated
equipment. Personal and demographic data were collected using
standardized questionnaires. Race/ethnicity was self-identified
(Table 5).
Unblinding
In order to make timely clinical decisions, aliquots of fasting and
2-hour OGTT or random plasma glucose (RPG) samples were
analyzed enzymatically at field center laboratories (12). Values
were unblinded if FPG exceeded 5.8 mg/dl (105 mg/dL)), if 2-
hour PG exceeded 11.1 mg/dl (200 mg/dL)), if RPG was
$8.9 mg/dl (160 mg/dL) or if any PG value was less than
2.5 mg/dl (45 mg/dL). Otherwise, women, caregivers, and
HAPO Study staff (except for laboratory personnel) remained
blinded to glucose values. To avoid center-to-center analytical
variation, aliquots of the OGTT glucose and C-peptide samples
were analyzed at the HAPO Central Laboratory [73]. Those
results were used for this report. A ‘‘Vitros 750’’ analyzer was used
for glucose analysis and serum C-peptide was assayed on an
Autodelfia instrument [73]. The technical errors for the glucose
and C-peptide measurements were 2.0 and 4.2%, respectively.
DNA sample collection, preparation, and genotyping
A blood sample for DNA extraction was collected into an
EDTA tube at 2-hours during the OGTT on women who
specifically consented to this. Samples were frozen and shipped to
Chicago. DNA was prepared using the automated Autopure LS
from Qiagen. For this study we selected the two populations
(Caucasians of European ancestry and Thai women from Bangok)
with the largest sample size and relatively homogenous ethnic
ancestry.
SNP selection. Single nucleotide polymorphisms (SNPs)
included in this study belong to three categories: (i) anonymous
candidate gene SNPs or haplotype tagging SNPs (htSNPs which
map to genes belonging to the inflammatory pathway (Table 2), (ii)
coding SNPs (cSNPs) that map to candidate genes (Table 3), and
(iii) candidate SNPs (candSNPs) which have demonstrated
evidence for association with inflammatory phenotypes in
previous studies (Table 3). Anonymous candidate gene SNPs
mapping to candidate genes or htSNPs were selected using the
HAPMAP Tagger function (http://www.hapmap.org/cgi-perl/
gbrowse/hapmap_B35/) to tag the entire genomic segment
encompassing a given candidate gene in Caucasians (i.e. the
CEPH trios genotyped by HAPMAP), Asian (Chinese and
Japanese HAPMAP samples), and African (Yoruban HAPMAP
trios) at an r2 of $0.8. A candidate gene region was identified as
the coding region of the gene plus 20 kb upstream and 15 kb
downstream of the gene. The SNPs consisted of 454 candidate
gene tagging SNPs (htSNPs, Table 2), 54 candidate and/or coding
Figure 1. Association results of maternal traits in the HAPO cohort. Blue diamonds correspond to association results for SNPs in the
complete cohort (All). The red squares correspond to association results for SNPs in the European ancestry cohort (Eur_Anc). The green triangles
correspond to association results for SNPs in the Thai cohort (Thai). The -log10p-value for each association test is shown along the y-axis, and the
location of each SNP is indicated along the x-axis. The genomic region included in the genetic analysis is illustrated below each panel of association
results (based on USC genome browser May 2004 (NCBI35/hg17) build). FPG= fasting plasma glucose levels during OGTT; All n = 5546, European
Ancestry n = 3834, and Thai n = 1712. 1-hour PG= 1-hour plasma glucose levels during OGTT; All n = 5543, European Ancestry n= 3833, and Thai
n = 1710. 1-hour CP= 1-hour c-peptide during OGTT; All n = 5549, European Ancestry n= 3836, and Thai n = 1713. HbA1c; All n = 5216, European
Ancestry n = 3648, and Thai n = 1568.
doi:10.1371/journal.pone.0032958.g001
Table 5. Baseline characteristics of study participants.
Belfast, UK Manchester, UK Brisbane, Australia Newcastle, Australia Bangkok, Thailand
Pregnant women 1288 1098 959 490 1695
Gestational age at OGTT (weeks) 29.061.2 28.461.0 28.161.2 28.061.5 28.161.8
Age at OGTT (years) 29.865.5 30.865.6 29.265.3 29.565.5 27.965.5
BMI at OGTT (kg/m2) 28.464.9 29.065.5 29.065.7 29.766.1 25.763.7
Mean arterial pressure at OGTT (mm Hg) 83.667.9 83.568.0 83.867.6 82.768.1 80.367.7
Fasting Plasma Glucose (mmol/l) 4.660.4 4.660.4 4.460.4 4.560.4 4.560.4
1-hour plasma glucose (mmol/L) 7.561.7 7.561.8 7.461.5 7.361.7 8.361.7
2-hour plasma glucose (mmol/L) 6.161.2 6.061.4 6.261.2 6.261.3 6.761.4
Fasting C-peptide (ug/L) 2.160.9 2.160.9 1.660.8 2.160.9 1.760.8
1-hour C-peptide (ug/L) 10.163.1 9.863.0 7.762.5 9.562.8 10.063.0
HbA1c (%) 4.860.4 4.960.3 4.860.4 4.860.4 4.560.6
doi:10.1371/journal.pone.0032958.t005
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SNPs (candSNPs, cSNPs, Table 5). In addition we genotyped 50
previously identified Ancestry Informative Markers (AIMs). At the
time of SNP selection neither results from GWA studies in T2D
and related phenotypes nor panels of SNP based AIMs were
available.
Genotyping. SNPs were genotyped using the Illumina
Goldengate Assay on 32 sample universal BeadChip and iScan
system (Illumina, San Diego CA) in a 1536 SNP bundle according
to the manufacturers’ recommendations. Each 96 well plate
consisted of 93 study samples and one CEPH (Centre d’Etude du
Polymorphisme Humain) trio that served as a genotyping control.
Two of the CEPH DNAs were randomly positioned on each tray
while one DNA was plated in a fixed position on each tray
allowing for unambiguous identification of each DNA tray and its
orientation. Initial genotyping was carried out using the
manufacturer supplied genotype clusters. Genotypes based on
these cluster definition were used to identify poor quality DNAs.
We defined poor quality DNAs as DNAs with p10GC,0.40,
p50GC,0.60 or call rates less than 0.65. The poor quality DNAs
were removed from the analysis as were two 96 well trays of DNAs
with high rates of gender and replication errors. Samples were re-
clustered and genotype clusters for each SNP were examined
visually and cluster boundaries were adjusted as necessary. Finally,
DNAs were re-genotyped using new cluster definitions. After re-
clustering individuals were excluded due to: (i) phenotypic
discrepancies including improper unblinding, nonsensical data,
incorrect ethnicity, or ‘‘bad ‘‘IDs, (ii) missing genotypes for .6%
of SNPs, or (iii) mom-baby pairs with Mendelian errors for .5%
of SNPs.
Of the 508 inflammatory gene SNPs that were submitted for
genotyping, 32 markers were dropped due to poor resolution of
genotyping clusters. A further 6 SNPs were dropped due to high
proportion of genotyping failures (.1% of DNA samples), and 12
SNPs were dropped due to low minor allele frequency
(MAF,0.01). Thus 458 SNPs fulfilled our quality control criteria.
The average call rate of the SNPs used in the association analyses
was 99.9% and average minor allele frequency (MAF) was 0.28.
The replication error rate in the Centre D’Etude du Polymor-
phisme Humain (CEPH) trio was ,0.01%. Of the 6218 unique
DNA samples submitted for genotyping 5549 subjects (1713 Thai
and 3836 Northern European ancestry) remained after data
cleaning. 60 DNA samples failed Illumina genotyping quality
scores, 441 samples had missing genotypes at greater than 6% of
SNPs and 168 samples were dropped due to excessive Mendelian
errors (.5%), or due to phenotypic discrepancies including
improper unblinding, nonsensical data, incorrect ethnicity, or
incorrect sample identifiers. Average call rate for the 5549 samples
used in the genetic analyses was .99%.
Genetic Analysis
Principal Component Analysis (PCA): We used SMARTPCA in
the EIGENSOFT software package to calculate principal
components for each subject using 145 AIMS. The AIMs
consisted of 50 previously identified AIMs and 95 independent
htSNPs from this study. These independent htSNPs were chosen
by selecting one SNP from each of the genomic regions
interrogated in the complete candidate gene 1536 SNP panel.
These genomic regions possessed the greatest sum of interpopu-
lation allele frequency differences in the three HapMap Phase I
populations, and were not in linkage disequilibrium (r2,0.3) with
any SNP showing evidence for association (p,0.01) with the six
primary phenotypes investigated (see below). This set of 145 SNPs
was sufficient to differentiate between the Thai and Caucasians,
although choosing a second SNP per genomic region that met the
first two conditions above and was not in linkage disequilibrium
(r2,0.3) with the first SNP selected from the region improved
performance. The principal components derived from these
analyses were used as covariates to adjust for ethnic variation in
the association tests.
Association Testing. We tested for association between
SNPs and six maternal phenotypes in the complete cohort while
adjusting for field center and ethnicity and in Thai and Caucasian
cohorts separately. Phenotypes tested were glucose levels (fasting,
1-hour and 2-hour), C-peptide levels (fasting and 1-hour), and
HbA1c levels. All phenotypic measurements were obtained at the
OGTT. Associations were assessed through linear regressions,
with single outcomes under an additive model using PLINK,
version 1.05 [74], integrated into the BC/SNPmax database,
version 2.5.9 (Biocomputing Platforms Ltd., Espoo, Finland).
Natural log (ln) transformation was used to achieve normal
distribution for C-peptide levels. Mendelian error checking of
genotypes was performed with PedCheck, version 1.00 [75]
through BC/SNPmax.
Two models were analyzed for each outcome. Model I was a
minimally adjusted model that included adjustment for field
center, ethnicity using the first two principal components and four
variables that are major covariates: maternal age, parity,
gestational age at OGTT, and neonatal gender. Model II was
the fully adjusted model, adjusting for all covariates included in
model I as well as MAP at OGTT, maternal BMI at OGTT, and
maternal height at OGTT.
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